<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31072060</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2073-4409</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>8</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cells</Title>
          <ISOAbbreviation>Cells</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GPCR-Hippo Signaling in Cancer.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">426</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells8050426</ELocationID>
        <Abstract>
          <AbstractText>The Hippo signaling pathway is involved in tissue size regulation and tumorigenesis. Genetic deletion or aberrant expression of some Hippo pathway genes lead to enhanced cell proliferation, tumorigenesis, and cancer metastasis. Recently, multiple studies have identified a wide range of upstream regulators of the Hippo pathway, including mechanical cues and ligands of G protein-coupled receptors (GPCRs). Through the activation related G proteins and possibly rearrangements of actin cytoskeleton, GPCR signaling can potently modulate the phosphorylation states and activity of YAP and TAZ, two homologous oncogenic transcriptional co-activators, and major effectors of the Hippo pathway. Herein, we summarize the network, regulation, and functions of GPCR-Hippo signaling, and we will also discuss potential anti-cancer therapies targeting GPCR-YAP signaling.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Jiaqian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China. jqluo15@fudan.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Fa-Xing</ForeName>
            <Initials>FX</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China. fxyu@fudan.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cells</MedlineTA>
        <NlmUniqueID>101600052</NlmUniqueID>
        <ISSNLinking>2073-4409</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">G protein-coupled receptor</Keyword>
        <Keyword MajorTopicYN="Y">GPCR</Keyword>
        <Keyword MajorTopicYN="Y">Hippo pathway</Keyword>
        <Keyword MajorTopicYN="Y">YAP/TAZ</Keyword>
        <Keyword MajorTopicYN="Y">anti-cancer therapy</Keyword>
        <Keyword MajorTopicYN="Y">cancer</Keyword>
        <Keyword MajorTopicYN="Y">signal transduction</Keyword>
        <Keyword MajorTopicYN="Y">tumorigenesis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31072060</ArticleId>
        <ArticleId IdType="pmc">PMC6563442</ArticleId>
        <ArticleId IdType="doi">10.3390/cells8050426</ArticleId>
        <ArticleId IdType="pii">cells8050426</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Johnson R., Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat. Rev. Drug Discov. 2014;13:63–79. doi: 10.1038/nrd4161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd4161</ArticleId>
            <ArticleId IdType="pmc">PMC4167640</ArticleId>
            <ArticleId IdType="pubmed">24336504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan D. The hippo signaling pathway in development and cancer. Dev. Cell. 2010;19:491–505. doi: 10.1016/j.devcel.2010.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2010.09.011</ArticleId>
            <ArticleId IdType="pmc">PMC3124840</ArticleId>
            <ArticleId IdType="pubmed">20951342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey K.F., Zhang X., Thomas D.M. The Hippo pathway and human cancer. Nat. Rev. Cancer. 2013;13:246–257. doi: 10.1038/nrc3458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3458</ArticleId>
            <ArticleId IdType="pubmed">23467301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F.X., Zhao B., Guan K.L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015;163:811–828. doi: 10.1016/j.cell.2015.10.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.10.044</ArticleId>
            <ArticleId IdType="pmc">PMC4638384</ArticleId>
            <ArticleId IdType="pubmed">26544935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., et al.  MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat. Commun. 2015;6:8357. doi: 10.1038/ncomms9357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms9357</ArticleId>
            <ArticleId IdType="pmc">PMC4600732</ArticleId>
            <ArticleId IdType="pubmed">26437443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., Li L., Tumaneng K., Wang C.-Y., Guan K.-L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP) Genes Dev. 2010;24:72–85. doi: 10.1101/gad.1843810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1843810</ArticleId>
            <ArticleId IdType="pmc">PMC2802193</ArticleId>
            <ArticleId IdType="pubmed">20048001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., Xie J., Ikenoue T., Yu J., Li L., et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–2761. doi: 10.1101/gad.1602907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1602907</ArticleId>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei Q.Y., Zhang H., Zhao B., Zha Z.Y., Bai F., Pei X.H., Zhao S., Xiong Y., Guan K.L. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol. Cell. Biol. 2008;28:2426–2436. doi: 10.1128/MCB.01874-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01874-07</ArticleId>
            <ArticleId IdType="pmc">PMC2268418</ArticleId>
            <ArticleId IdType="pubmed">18227151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamar J.M., Stern P., Liu H., Schindler J.W., Jiang Z.-G., Hynes R.O. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc. Natl. Acad. Sci. USA. 2012;109:E2441–E2450. doi: 10.1073/pnas.1212021109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1212021109</ArticleId>
            <ArticleId IdType="pmc">PMC3443162</ArticleId>
            <ArticleId IdType="pubmed">22891335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Gao Y., Li P., Shi Z., Guo T., Li F., Han X., Feng Y., Zheng C., Wang Z., et al.  VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24:331–343. doi: 10.1038/cr.2014.10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2014.10</ArticleId>
            <ArticleId IdType="pmc">PMC3945886</ArticleId>
            <ArticleId IdType="pubmed">24458094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koontz L.M., Liu-Chittenden Y., Yin F., Zheng Y.G., Yu J.Z., Huang B., Chen Q., Wu S., Pan D.J. The Hippo Effector Yorkie Controls Normal Tissue Growth by Antagonizing Scalloped-Mediated Default Repression. Dev. Cell. 2013;25:388–401. doi: 10.1016/j.devcel.2013.04.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2013.04.021</ArticleId>
            <ArticleId IdType="pmc">PMC3705890</ArticleId>
            <ArticleId IdType="pubmed">23725764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Striedinger K., VandenBerg S.R., Baia G.S., McDermott M.W., Gutmann D.H., Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia. 2008;10:1204–1212. doi: 10.1593/neo.08642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/neo.08642</ArticleId>
            <ArticleId IdType="pmc">PMC2570596</ArticleId>
            <ArticleId IdType="pubmed">18953429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F., Yu J., Zheng Y., Chen Q., Zhang N., Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013;154:1342–1355. doi: 10.1016/j.cell.2013.08.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.08.025</ArticleId>
            <ArticleId IdType="pmc">PMC3835333</ArticleId>
            <ArticleId IdType="pubmed">24012335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J., Zheng Y., Dong J., Klusza S., Deng W.-M., Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev. Cell. 2010;18:288–299. doi: 10.1016/j.devcel.2009.12.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2009.12.012</ArticleId>
            <ArticleId IdType="pmc">PMC2858562</ArticleId>
            <ArticleId IdType="pubmed">20159598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan S.W., Lim C.J., Chong Y.F., Pobbati A.V., Huang C., Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J. Biol. Chem. 2011;286:7018–7026. doi: 10.1074/jbc.C110.212621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.C110.212621</ArticleId>
            <ArticleId IdType="pmc">PMC3044958</ArticleId>
            <ArticleId IdType="pubmed">21224387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paramasivam M., Sarkeshik A., Yates J.R., 3rd, Fernandes M.J., McCollum D. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol. Biol. Cell. 2011;22:3725–3733. doi: 10.1091/mbc.e11-04-0300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.e11-04-0300</ArticleId>
            <ArticleId IdType="pmc">PMC3183025</ArticleId>
            <ArticleId IdType="pubmed">21832154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Huang J., Chen J. Angiomotin-like proteins associate with and negatively regulate YAP1. J. Biol. Chem. 2011;286:4364–4370. doi: 10.1074/jbc.C110.205401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.C110.205401</ArticleId>
            <ArticleId IdType="pmc">PMC3039387</ArticleId>
            <ArticleId IdType="pubmed">21187284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., Li L., Lu Q., Wang L.H., Liu C.Y., Lei Q., Guan K.L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011;25:51–63. doi: 10.1101/gad.2000111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.2000111</ArticleId>
            <ArticleId IdType="pmc">PMC3012936</ArticleId>
            <ArticleId IdType="pubmed">21205866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polesello C., Huelsmann S., Brown N.H., Tapon N. The Drosophila RASSF homolog antagonizes the hippo pathway. Curr. Biol. 2006;16:2459–2465. doi: 10.1016/j.cub.2006.10.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2006.10.060</ArticleId>
            <ArticleId IdType="pmc">PMC1828611</ArticleId>
            <ArticleId IdType="pubmed">17174922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlahov N., Scrace S., Soto M.S., Grawenda A.M., Bradley L., Pankova D., Papaspyropoulos A., Yee K.S., Buffa F., Goding C.R., et al.  Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion. Curr. Biol. 2015;25:3019–3034. doi: 10.1016/j.cub.2015.09.072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2015.09.072</ArticleId>
            <ArticleId IdType="pmc">PMC4683097</ArticleId>
            <ArticleId IdType="pubmed">26549256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khokhlatchev A., Rabizadeh S., Xavier R., Nedwidek M., Chen T., Zhang X.F., Seed B., Avruch J. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 2002;12:253–265. doi: 10.1016/S0960-9822(02)00683-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0960-9822(02)00683-8</ArticleId>
            <ArticleId IdType="pubmed">11864565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z., Qiu Y., Lin K.C., Kumar A., Placone J.K., Fang C., Wang K.-C., Lu S., Pan M., Hong A.W., et al.  RAP2 mediates mechanoresponses of the Hippo pathway. Nature. 2018;560:655–660. doi: 10.1038/s41586-018-0444-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0444-0</ArticleId>
            <ArticleId IdType="pmc">PMC6128698</ArticleId>
            <ArticleId IdType="pubmed">30135582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupont S., Morsut L., Aragona M., Enzo E., Giulitti S., Cordenonsi M., Zanconato F., Le Digabel J., Forcato M., Bicciato S., et al.  Role of YAP/TAZ in mechanotransduction. Nature. 2011;474:179–183. doi: 10.1038/nature10137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10137</ArticleId>
            <ArticleId IdType="pubmed">21654799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao D., Zhai P., Del Re D.P., Sciarretta S., Yabuta N., Nojima H., Lim D.-S., Pan D., Sadoshima J. A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response. Nat. Commun. 2014;5:3315. doi: 10.1038/ncomms4315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms4315</ArticleId>
            <ArticleId IdType="pmc">PMC3962829</ArticleId>
            <ArticleId IdType="pubmed">24525530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma B., Chen Y., Chen L., Cheng H., Mu C., Li J., Gao R., Zhou C., Cao L., Liu J., et al.  Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat. Cell Biol. 2014;17:95–103. doi: 10.1038/ncb3073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3073</ArticleId>
            <ArticleId IdType="pubmed">25438054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma B., Cheng H., Gao R., Mu C., Chen L., Wu S., Chen Q., Zhu Y. Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-β signalling pathways. Nat. Commun. 2016;7:11123. doi: 10.1038/ncomms11123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms11123</ArticleId>
            <ArticleId IdType="pmc">PMC4821889</ArticleId>
            <ArticleId IdType="pubmed">27030211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin K.C., Moroishi T., Meng Z., Jeong H.-S., Plouffe S.W., Sekido Y., Han J., Park H.W., Guan K.-L. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nat. Cell Biol. 2017;19:996–1002. doi: 10.1038/ncb3581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3581</ArticleId>
            <ArticleId IdType="pmc">PMC5541894</ArticleId>
            <ArticleId IdType="pubmed">28752853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu H., Wei L., Fan F., Ji S., Zhang S., Geng J., Hong L., Fan X., Chen Q., Tian J., et al.  Integration of Hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis. Nat. Commun. 2015;6:6239. doi: 10.1038/ncomms7239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms7239</ArticleId>
            <ArticleId IdType="pubmed">25695629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong A.W., Meng Z., Yuan H.-X., Plouffe S.W., Moon S., Kim W., Jho E.-H., Guan K.-L. Osmotic stress-induced phosphorylation by NLK at Ser128 activates YAP. EMBO Rep. 2017;18:72–86. doi: 10.15252/embr.201642681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embr.201642681</ArticleId>
            <ArticleId IdType="pmc">PMC5210094</ArticleId>
            <ArticleId IdType="pubmed">27979971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller E., Yang J., DeRan M., Wu C., Su A.I., Bonamy G.M.C., Liu J., Peters E.C., Wu X. Identification of Serum-Derived Sphingosine-1-Phosphate as a Small Molecule Regulator of YAP. Chem. Biol. 2012;19:955–962. doi: 10.1016/j.chembiol.2012.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2012.07.005</ArticleId>
            <ArticleId IdType="pubmed">22884261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F.-X., Mo J.-S., Guan K.-L. Upstream regulators of the Hippo pathway. Cell Cycle. 2012;11:4097–4098. doi: 10.4161/cc.22322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.22322</ArticleId>
            <ArticleId IdType="pmc">PMC3524194</ArticleId>
            <ArticleId IdType="pubmed">23075495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F.-X., Zhao B., Panupinthu N., Jewell J.L., Lian I., Wang L.H., Zhao J., Yuan H., Tumaneng K., Li H., et al.  Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150:780–791. doi: 10.1016/j.cell.2012.06.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.06.037</ArticleId>
            <ArticleId IdType="pmc">PMC3433174</ArticleId>
            <ArticleId IdType="pubmed">22863277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F., Cordenonsi M., Piccolo S. YAP/TAZ at the Roots of Cancer. Cancer Cell. 2016;29:783–803. doi: 10.1016/j.ccell.2016.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC6186419</ArticleId>
            <ArticleId IdType="pubmed">27300434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moroishi T., Hansen C.G., Guan K.L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer. 2015;15:73–79. doi: 10.1038/nrc3876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3876</ArticleId>
            <ArticleId IdType="pmc">PMC4562315</ArticleId>
            <ArticleId IdType="pubmed">25592648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F.-X., Meng Z., Plouffe S.W., Guan K.-L. Hippo Pathway Regulation of Gastrointestinal Tissues. Annu. Rev. Physiol. 2015;77:201–227. doi: 10.1146/annurev-physiol-021014-071733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-physiol-021014-071733</ArticleId>
            <ArticleId IdType="pubmed">25293527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N., Bai H., David K.K., Dong J., Zheng Y., Cai J., Giovannini M., Liu P., Anders R.A., Pan D. The Merlin/NF2 Tumor Suppressor Functions through the YAP Oncoprotein to Regulate Tissue Homeostasis in Mammals. Dev. Cell. 2010;19:27–38. doi: 10.1016/j.devcel.2010.06.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2010.06.015</ArticleId>
            <ArticleId IdType="pmc">PMC2925178</ArticleId>
            <ArticleId IdType="pubmed">20643348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K.-P., Lee J.-H., Kim T.-S., Kim T.-H., Park H.-D., Byun J.-S., Kim M.-C., Jeong W.-I., Calvisi D.F., Kim J.-M., et al.  The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc. Natl. Acad. Sci. USA. 2010;107:8248–8253. doi: 10.1073/pnas.0912203107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0912203107</ArticleId>
            <ArticleId IdType="pmc">PMC2889558</ArticleId>
            <ArticleId IdType="pubmed">20404163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D., Conrad C., Xia F., Park J.-S., Payer B., Yin Y., Lauwers G.Y., Thasler W., Lee J.T., Avruch J., et al.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009;16:425–438. doi: 10.1016/j.ccr.2009.09.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.09.026</ArticleId>
            <ArticleId IdType="pmc">PMC3023165</ArticleId>
            <ArticleId IdType="pubmed">19878874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>St John M.A., Tao W., Fei X., Fukumoto R., Carcangiu M.L., Brownstein D.G., Parlow A.F., McGrath J., Xu T. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat.Genet. 1999;21:182–186. doi: 10.1038/5965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/5965</ArticleId>
            <ArticleId IdType="pubmed">9988269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M., Hamada K., Kawahara K., Sasaki M., Noguchi F., Chiba S., Mizuno K., Suzuki S.O., Dong Y., Tokuda M., et al.  Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. J. Clin. Invest. 2012;122:4505–4518. doi: 10.1172/JCI63735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI63735</ArticleId>
            <ArticleId IdType="pmc">PMC3533542</ArticleId>
            <ArticleId IdType="pubmed">23143302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knight J.F., Sung V.Y.C., Kuzmin E., Couzens A.L., de Verteuil D.A., Ratcliffe C.D.H., Coelho P.P., Johnson R.M., Samavarchi-Tehrani P., Gruosso T., et al.  KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. Cell Rep. 2018;22:3191–3205. doi: 10.1016/j.celrep.2018.02.095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.02.095</ArticleId>
            <ArticleId IdType="pmc">PMC5873529</ArticleId>
            <ArticleId IdType="pubmed">29562176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Weyden L., Tachibana K.K., Gonzalez M.A., Adams D.J., Ng B.L., Petty R., Venkitaraman A.R., Arends M.J., Bradley A. The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol. Cell. Biol. 2005;25:8356–8367. doi: 10.1128/MCB.25.18.8356-8367.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.25.18.8356-8367.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1234312</ArticleId>
            <ArticleId IdType="pubmed">16135822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Weyden L., Arends M.J., Dovey O.M., Harrison H.L., Lefebvre G., Conte N., Gergely F.V., Bradley A., Adams D.J. Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumourigenesis. Oncogene. 2008;27:4503–4508. doi: 10.1038/onc.2008.94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2008.94</ArticleId>
            <ArticleId IdType="pmc">PMC3706934</ArticleId>
            <ArticleId IdType="pubmed">18391979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Weyden L., Papaspyropoulos A., Poulogiannis G., Rust A.G., Rashid M., Adams D.J., Arends M.J., O’Neill E. Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis. Cancer Res. 2012;72:3817–3827. doi: 10.1158/0008-5472.CAN-11-3343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-3343</ArticleId>
            <ArticleId IdType="pmc">PMC4067151</ArticleId>
            <ArticleId IdType="pubmed">22710434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., Gayyed M.F., Anders R.A., Maitra A., Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–1133. doi: 10.1016/j.cell.2007.07.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.07.019</ArticleId>
            <ArticleId IdType="pmc">PMC2666353</ArticleId>
            <ArticleId IdType="pubmed">17889654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overholtzer M., Zhang J., Smolen G.A., Muir B., Li W., Sgroi D.C., Deng C.-X., Brugge J.S., Haber D.A. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. USA. 2006;103:12405–12410. doi: 10.1073/pnas.0605579103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0605579103</ArticleId>
            <ArticleId IdType="pmc">PMC1533802</ArticleId>
            <ArticleId IdType="pubmed">16894141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan S.W., Lim C.J., Guo K., Ng C.P., Lee I., Hunziker W., Zeng Q., Hong W. A Role for TAZ in Migration, Invasion, and Tumorigenesis of Breast Cancer Cells. Cancer Res. 2008;68:2592–2598. doi: 10.1158/0008-5472.CAN-07-2696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2696</ArticleId>
            <ArticleId IdType="pubmed">18413727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., Inui M., Montagner M., Parenti A.R., Poletti A., et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell. 2011;147:759–772. doi: 10.1016/j.cell.2011.09.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.09.048</ArticleId>
            <ArticleId IdType="pubmed">22078877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dawood S., Austin L., Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology. 2014;28:1101–1107, 1110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25510809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlegelmilch K., Mohseni M., Kirak O., Pruszak J., Rodriguez J.R., Zhou D., Kreger B.T., Vasioukhin V., Avruch J., Brummelkamp T.R., et al.  Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell. 2011;144:782–795. doi: 10.1016/j.cell.2011.02.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.031</ArticleId>
            <ArticleId IdType="pmc">PMC3237196</ArticleId>
            <ArticleId IdType="pubmed">21376238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Hateren N.J., Das R.M., Hautbergue G.M., Borycki A.-G., Placzek M., Wilson S.A. FatJ acts via the Hippo mediator Yap1 to restrict the size of neural progenitor cell pools. Development. 2011;138:1893–1902. doi: 10.1242/dev.064204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.064204</ArticleId>
            <ArticleId IdType="pmc">PMC3082296</ArticleId>
            <ArticleId IdType="pubmed">21521736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heallen T., Zhang M., Wang J., Bonilla-Claudio M., Klysik E., Johnson R.L., Martin J.F. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science. 2011;332:458–461. doi: 10.1126/science.1199010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1199010</ArticleId>
            <ArticleId IdType="pmc">PMC3133743</ArticleId>
            <ArticleId IdType="pubmed">21512031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judson R.N., Tremblay A.M., Knopp P., White R.B., Urcia R., De Bari C., Zammit P.S., Camargo F.D., Wackerhage H. The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. J. Cell Sci. 2012;125:6009–6019. doi: 10.1242/jcs.109546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.109546</ArticleId>
            <ArticleId IdType="pmc">PMC3585517</ArticleId>
            <ArticleId IdType="pubmed">23038772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J., Zhang N., Zheng Y., de Wilde R.F., Maitra A., Pan D. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010;24:2383–2388. doi: 10.1101/gad.1978810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1978810</ArticleId>
            <ArticleId IdType="pmc">PMC2964748</ArticleId>
            <ArticleId IdType="pubmed">21041407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez-L A., Northcott P.A., Dalton J., Fraga C., Ellison D., Angers S., Taylor M.D., Kenney A.M. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev. 2009;23:2729–2741. doi: 10.1101/gad.1824509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1824509</ArticleId>
            <ArticleId IdType="pmc">PMC2788333</ArticleId>
            <ArticleId IdType="pubmed">19952108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhat K.P.L., Salazar K.L., Balasubramaniyan V., Wani K., Heathcock L., Hollingsworth F., James J.D., Gumin J., Diefes K.L., Kim S.H., et al.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011;25:2594–2609. doi: 10.1101/gad.176800.111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.176800.111</ArticleId>
            <ArticleId IdType="pmc">PMC3248681</ArticleId>
            <ArticleId IdType="pubmed">22190458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S., Ajani J.A., Honjo S., Maru D.M., Chen Q., Scott A.W., Heallen T.R., Xiao L., Hofstetter W.L., Weston B., et al.  Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties. Cancer Res. 2014;74:4170–4182. doi: 10.1158/0008-5472.CAN-13-3569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-3569</ArticleId>
            <ArticleId IdType="pmc">PMC4136429</ArticleId>
            <ArticleId IdType="pubmed">24906622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Wolfe A., Septer S., Edwards G., Zhong X., Bashar Abdulkarim A., Ranganathan S., Apte U. Deregulation of Hippo kinase signalling in Human hepatic malignancies. Liver Int. 2012;32:38–47. doi: 10.1111/j.1478-3231.2011.02646.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1478-3231.2011.02646.x</ArticleId>
            <ArticleId IdType="pmc">PMC4175712</ArticleId>
            <ArticleId IdType="pubmed">22098159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Díaz-Martín J., López-García M.Á., Romero-Pérez L., Atienza-Amores M.R., Pecero M.L., Castilla M.Á., Biscuola M., Santón A., Palacios J. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr. Relat. Cancer. 2015;22:443–454. doi: 10.1530/ERC-14-0456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-14-0456</ArticleId>
            <ArticleId IdType="pubmed">25870251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C.-Y., Yu T., Huang Y., Cui L., Hong W. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer. J. Biol. Chem. 2017;292:9420–9430. doi: 10.1074/jbc.M117.783787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M117.783787</ArticleId>
            <ArticleId IdType="pmc">PMC5454120</ArticleId>
            <ArticleId IdType="pubmed">28408625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao S., Wang H., Shi Z., Dong A., Zhang W., Song X., He F., Wang Y., Zhang Z., Wang W., et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25:166–180. doi: 10.1016/j.ccr.2014.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2014.01.010</ArticleId>
            <ArticleId IdType="pubmed">24525233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noguchi S., Saito A., Horie M., Mikami Y., Suzuki H.I., Morishita Y., Ohshima M., Abiko Y., Mattsson J.S.M., Konig H., et al.  An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non-Small Cell Lung Cancer. Clin.Cancer Res. 2014;20:4660–4672. doi: 10.1158/1078-0432.CCR-13-3328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-3328</ArticleId>
            <ArticleId IdType="pubmed">24951773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng H., Zhang Z., Rodriguez-Barrueco R., Borczuk A., Liu H., Yu J., Silva J.M., Cheng S.K., Perez-Soler R., Halmos B. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget. 2016;7:28976–28988. doi: 10.18632/oncotarget.6721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.6721</ArticleId>
            <ArticleId IdType="pmc">PMC5045371</ArticleId>
            <ArticleId IdType="pubmed">26716514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orr B.A., Bai H., Odia Y., Jain D., Anders R.A., Eberhart C.G. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J. Neuropathol. Exp. Neurol. 2011;70:568–577. doi: 10.1097/NEN.0b013e31821ff8d8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e31821ff8d8</ArticleId>
            <ArticleId IdType="pmc">PMC3130608</ArticleId>
            <ArticleId IdType="pubmed">21666501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu M.Z., Yao T.-J., Lee N.P.Y., Ng I.O.L., Chan Y.-T., Zender L., Lowe S.W., Poon R.T.P., Luk J.M. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576–4585. doi: 10.1002/cncr.24495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.24495</ArticleId>
            <ArticleId IdType="pmc">PMC2811690</ArticleId>
            <ArticleId IdType="pubmed">19551889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K., Lee K.-B., Jung H.Y., Yi N.-J., Lee K.-W., Suh K.-S., Jang J.-J. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas. BMC Cancer. 2017;17:441.  doi: 10.1186/s12885-017-3431-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-017-3431-1</ArticleId>
            <ArticleId IdType="pmc">PMC5481924</ArticleId>
            <ArticleId IdType="pubmed">28645247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X.-L., Zuo R., Ou W.-B. The hippo pathway provides novel insights into lung cancer and mesothelioma treatment. J. Cancer Res. Clin. Oncol. 2018;144:2097–2106. doi: 10.1007/s00432-018-2727-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-018-2727-0</ArticleId>
            <ArticleId IdType="pubmed">30073421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Song X., Li X., Wu C., Jiang J. Yes-Associated Protein 1 as a Novel Prognostic Biomarker for Gastrointestinal Cancer: A Meta-Analysis. BioMed Res. Int. 2018;2018:4039173. doi: 10.1155/2018/4039173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/4039173</ArticleId>
            <ArticleId IdType="pmc">PMC6261404</ArticleId>
            <ArticleId IdType="pubmed">30539010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong R., Yu F.-X. Targeting the Hippo Pathway for Anti-cancer Therapies. Curr. Med. Chem. 2015;22:4104–4117. doi: 10.2174/0929867322666151002112256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/0929867322666151002112256</ArticleId>
            <ArticleId IdType="pubmed">26429069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim M.H., Kim J. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell. Mol. Life Sci. 2017;74:1457–1474. doi: 10.1007/s00018-016-2412-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2412-x</ArticleId>
            <ArticleId IdType="pubmed">27826640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans D.G.R. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II] Genet. Med. 2009;11:599–610. doi: 10.1097/GIM.0b013e3181ac9a27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/GIM.0b013e3181ac9a27</ArticleId>
            <ArticleId IdType="pubmed">19652604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thurneysen C., Opitz I., Kurtz S., Weder W., Stahel R.A., Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer. 2009;64:140–147. doi: 10.1016/j.lungcan.2008.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2008.08.014</ArticleId>
            <ArticleId IdType="pubmed">18835652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanas M.R., Ma S., Jadaan F.O., Ng C.K., Weigelt B., Reis-Filho J.S., Rubin B.P. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene. 2016;35:929–938. doi: 10.1038/onc.2015.148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.148</ArticleId>
            <ArticleId IdType="pmc">PMC4983459</ArticleId>
            <ArticleId IdType="pubmed">25961935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Errani C., Zhang L., Sung Y.S., Hajdu M., Singer S., Maki R.G., Healey J.H., Antonescu C.R. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50:644–653. doi: 10.1002/gcc.20886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.20886</ArticleId>
            <ArticleId IdType="pmc">PMC3264678</ArticleId>
            <ArticleId IdType="pubmed">21584898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidel C., Schagdarsurengin U., Blümke K., Würl P., Pfeifer G.P., Hauptmann S., Taubert H., Dammann R. Frequent hypermethylation of MST1 andMST2 in soft tissue sarcoma. Mol. Carcinog. 2007;46:865–871. doi: 10.1002/mc.20317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.20317</ArticleId>
            <ArticleId IdType="pubmed">17538946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi Y., Miyoshi Y., Takahata C., Irahara N., Taguchi T., Tamaki Y., Noguchi S. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin. Cancer Res. 2005;11:1380–1385. doi: 10.1158/1078-0432.CCR-04-1773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-1773</ArticleId>
            <ArticleId IdType="pubmed">15746036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Z., Li X., Hu J., Zhou W., Jiang Y., Li G., Lu D. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci. Res. 2006;56:450–458. doi: 10.1016/j.neures.2006.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neures.2006.09.006</ArticleId>
            <ArticleId IdType="pubmed">17049657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Vega F., Mina M., Armenia J., Chatila W.K., Luna A., La K.C., Dimitriadoy S., Liu D.L., Kantheti H.S., Saghafinia S., et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173:321–337. doi: 10.1016/j.cell.2018.03.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.03.035</ArticleId>
            <ArticleId IdType="pmc">PMC6070353</ArticleId>
            <ArticleId IdType="pubmed">29625050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grawenda A.M., O’Neill E. Clinical utility of RASSF1A methylation in human malignancies. Br. J. Cancer. 2015;113:372–381. doi: 10.1038/bjc.2015.221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2015.221</ArticleId>
            <ArticleId IdType="pmc">PMC4522630</ArticleId>
            <ArticleId IdType="pubmed">26158424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu H., Cheng X., Niu X., Zhang Y., Guan J., Liu X., Tao S., Wang Y., Zhang C. Proton-sensing GPCR-YAP Signalling Promotes Cell Proliferation and Survival. Int. J. Biol. Sci. 2015;11:1181–1189. doi: 10.7150/ijbs.12500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.12500</ArticleId>
            <ArticleId IdType="pmc">PMC4551754</ArticleId>
            <ArticleId IdType="pubmed">26327812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anakk S., Bhosale M., Schmidt V.A., Johnson R.L., Finegold M.J., Moore D.D. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 2013;5:1060–1069. doi: 10.1016/j.celrep.2013.10.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2013.10.030</ArticleId>
            <ArticleId IdType="pmc">PMC3961013</ArticleId>
            <ArticleId IdType="pubmed">24268772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thirunavukkarasan M., Wang C., Rao A., Hind T., Teo Y.R., Siddiquee A.A.-M., Goghari M.A.I., Kumar A.P., Herr D.R. Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells. PLoS ONE. 2017;12:e0186334.  doi: 10.1371/journal.pone.0186334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0186334</ArticleId>
            <ArticleId IdType="pmc">PMC5648159</ArticleId>
            <ArticleId IdType="pubmed">29049318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koo J.H., Guan K.-L. Interplay between YAP/TAZ and Metabolism. Cell Metab. 2018;28:196–206. doi: 10.1016/j.cmet.2018.07.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2018.07.010</ArticleId>
            <ArticleId IdType="pubmed">30089241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu O.M., Miyamoto S., Brown J.H. Myocardin-Related Transcription Factor A and Yes-Associated Protein Exert Dual Control in G Protein-Coupled Receptor- and RhoA-Mediated Transcriptional Regulation and Cell Proliferation. Mol. Cell. Biol. 2016;36:39–49. doi: 10.1128/MCB.00772-15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00772-15</ArticleId>
            <ArticleId IdType="pmc">PMC4702594</ArticleId>
            <ArticleId IdType="pubmed">26459764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wennmann D.O., Vollenbröker B., Eckart A.K., Bonse J., Erdmann F., Wolters D.A., Schenk L.K., Schulze U., Kremerskothen J., Weide T., et al.  The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes. Cell Death Dis. 2014;5:e1519. doi: 10.1038/cddis.2014.476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.476</ArticleId>
            <ArticleId IdType="pmc">PMC4260734</ArticleId>
            <ArticleId IdType="pubmed">25393475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z., Liu P., Zhou X., Wang T., Feng X., Sun Y.-P., Xiong Y., Yuan H.-X., Guan K.-L. Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ. Cancer Res. 2017;77:2413–2423. doi: 10.1158/0008-5472.CAN-16-3229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-3229</ArticleId>
            <ArticleId IdType="pmc">PMC6724531</ArticleId>
            <ArticleId IdType="pubmed">28249901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo J.-S., Yu F.-X., Gong R., Brown J.H., Guan K.-L. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs) Genes Dev. 2012;26:2138–2143. doi: 10.1101/gad.197582.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.197582.112</ArticleId>
            <ArticleId IdType="pmc">PMC3465735</ArticleId>
            <ArticleId IdType="pubmed">22972936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langenhan T., Aust G., Hamann J. Sticky Signaling—Adhesion Class G Protein-Coupled Receptors Take the Stage. Sci. Signal. 2013;6 doi: 10.1126/scisignal.2003825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2003825</ArticleId>
            <ArticleId IdType="pubmed">23695165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X., Wang S., Wang Z., Feng X., Liu P., Lv X.-B., Li F., Yu F.-X., Sun Y., Yuan H., et al.  Estrogen regulates Hippo signaling via GPER in breast cancer. J. Clin. Invest. 2015;125:2123–2135. doi: 10.1172/JCI79573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI79573</ArticleId>
            <ArticleId IdType="pmc">PMC4463207</ArticleId>
            <ArticleId IdType="pubmed">25893606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai H., Xu Y. The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun. Signal. 2013;11:31. doi: 10.1186/1478-811X-11-31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1478-811X-11-31</ArticleId>
            <ArticleId IdType="pmc">PMC3655373</ArticleId>
            <ArticleId IdType="pubmed">23618389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng J.-C., Wang E.Y., Yi Y., Thakur A., Tsai S.-H., Hoodless P.A. S1P Stimulates Proliferation by Upregulating CTGF Expression through S1PR2-Mediated YAP Activation. Mol. Cancer Res. 2018;16:1543–1555. doi: 10.1158/1541-7786.MCR-17-0681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-17-0681</ArticleId>
            <ArticleId IdType="pubmed">29903770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou P.-J., Xue W., Peng J., Wang Y., Wei L., Yang Z., Zhu H.H., Fang Y.-X., Gao W.-Q. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway. J. Exp. Clin. Cancer Res. 2017;36:139. doi: 10.1186/s13046-017-0609-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-017-0609-y</ArticleId>
            <ArticleId IdType="pmc">PMC5633884</ArticleId>
            <ArticleId IdType="pubmed">29017577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nag J., Bar-Shavit R. Transcriptional Landscape of PARs in Epithelial Malignancies. Int. J. Mol. Sci. 2018;19:3451.  doi: 10.3390/ijms19113451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19113451</ArticleId>
            <ArticleId IdType="pmc">PMC6275037</ArticleId>
            <ArticleId IdType="pubmed">30400241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H.-B., Kim M., Park Y.-S., Park I., Kim T., Yang S.-Y., Cho C.J., Hwang D., Jung J.-H., Markowitz S.D., et al.  Prostaglandin E2 Activates YAP and a Positive-Signaling Loop to Promote Colon Regeneration After Colitis but Also Carcinogenesis in Mice. Gastroenterology. 2017;152:616–630. doi: 10.1053/j.gastro.2016.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2016.11.005</ArticleId>
            <ArticleId IdType="pmc">PMC5285392</ArticleId>
            <ArticleId IdType="pubmed">27864128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu G., Wang Y., Li W., Cao Y., Xu J., Hu Z., Hao Y., Hu L., Sun Y. COX-2 Forms Regulatory Loop with YAP to Promote Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells. Neoplasia. 2018;20:324–334. doi: 10.1016/j.neo.2017.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2017.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC5909490</ArticleId>
            <ArticleId IdType="pubmed">29505957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh M., Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases (Review) Int. J. Mol. Med. 2017;40:587–606. doi: 10.3892/ijmm.2017.3071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2017.3071</ArticleId>
            <ArticleId IdType="pmc">PMC5547940</ArticleId>
            <ArticleId IdType="pubmed">28731148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng C.-H., Chen X.-M., Zhang F.-B., Zhao C., Tu S.-S. Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway. Cell Biol. Int. 2018;42:1386–1394. doi: 10.1002/cbin.11024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbin.11024</ArticleId>
            <ArticleId IdType="pubmed">29972256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger J.A., Kipps T.J. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–1767. doi: 10.1182/blood-2005-08-3182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2005-08-3182</ArticleId>
            <ArticleId IdType="pubmed">16269611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almofti A., Uchida D., Begum N.M., Tomizuka Y., Iga H., Yoshida H., Sato M. The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int. J. Oncol. 2004;25:65–71. doi: 10.3892/ijo.25.1.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.25.1.65</ArticleId>
            <ArticleId IdType="pubmed">15201990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raghuwanshi S.K., Su Y., Singh V., Haynes K., Richmond A., Richardson R.M. The Chemokine Receptors CXCR1 and CXCR2 Couple to Distinct G Protein-Coupled Receptor Kinases To Mediate and Regulate Leukocyte Functions. J. Immunol. 2012;189:2824–2832. doi: 10.4049/jimmunol.1201114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1201114</ArticleId>
            <ArticleId IdType="pmc">PMC3436986</ArticleId>
            <ArticleId IdType="pubmed">22869904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Z., Swaby R.F., Liang Y., Yu S., Liu S., Lu K.H., Bast R.C., Mills G.B., Fang X. Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer. Cancer Res. 2006;66:2740–2748. doi: 10.1158/0008-5472.CAN-05-2947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-2947</ArticleId>
            <ArticleId IdType="pubmed">16510595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharif G.M., Schmidt M.O., Yi C., Hu Z., Haddad B.R., Glasgow E., Riegel A.T., Wellstein A. Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling. Oncogene. 2015;34:5879–5889. doi: 10.1038/onc.2015.44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.44</ArticleId>
            <ArticleId IdType="pmc">PMC4573390</ArticleId>
            <ArticleId IdType="pubmed">25772246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uemura H., Hasumi H., Ishiguro H., Teranishi J.-I., Miyoshi Y., Kubota Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate. 2006;66:822–830. doi: 10.1002/pros.20407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pros.20407</ArticleId>
            <ArticleId IdType="pubmed">16482568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saikawa S., Kaji K., Nishimura N., Seki K., Sato S., Nakanishi K., Kitagawa K., Kawaratani H., Kitade M., Moriya K., et al.  Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. Cancer Lett. 2018;434:120–129. doi: 10.1016/j.canlet.2018.07.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2018.07.021</ArticleId>
            <ArticleId IdType="pubmed">30031758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Hong Y., Shao S., Zhang K., Hong W. FFAR1-and FFAR4-dependent activation of Hippo pathway mediates DHA-induced apoptosis of androgen-independent prostate cancer cells. Biochem. Biophys. Res. Commun. 2018;506:590–596. doi: 10.1016/j.bbrc.2018.10.088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.10.088</ArticleId>
            <ArticleId IdType="pubmed">30366669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dethlefsen C., Hansen L.S., Lillelund C., Andersen C., Gehl J., Christensen J.F., Pedersen B.K., Hojman P. Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce Risks of Breast Cancer Development. Cancer Res. 2017;77:4894–4904. doi: 10.1158/0008-5472.CAN-16-3125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-3125</ArticleId>
            <ArticleId IdType="pubmed">28887324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F.-X., Zhang Y., Park H.W., Jewell J.L., Chen Q., Deng Y., Pan D., Taylor S.S., Lai Z.-C., Guan K.-L. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 2013;27:1223–1232. doi: 10.1101/gad.219402.113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.219402.113</ArticleId>
            <ArticleId IdType="pmc">PMC3690396</ArticleId>
            <ArticleId IdType="pubmed">23752589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim M., Kim M., Lee S., Kuninaka S., Saya H., Lee H., Lee S., Lim D.-S. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. EMBO J. 2013;32:1543–1555. doi: 10.1038/emboj.2013.102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emboj.2013.102</ArticleId>
            <ArticleId IdType="pmc">PMC3671250</ArticleId>
            <ArticleId IdType="pubmed">23644383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iglesias-Bartolome R., Torres D., Marone R., Feng X., Martin D., Simaan M., Chen M., Weinstein L.S., Taylor S.S., Molinolo A.A., et al.  Inactivation of a Gα(s)-PKA tumour suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. Nat. Cell Biol. 2015;17:793–803. doi: 10.1038/ncb3164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3164</ArticleId>
            <ArticleId IdType="pmc">PMC4449815</ArticleId>
            <ArticleId IdType="pubmed">25961504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong R., Hong A.W., Plouffe S.W., Zhao B., Liu G., Yu F.-X., Xu Y., Guan K.-L. Opposing roles of conventional and novel PKC isoforms in Hippo-YAP pathway regulation. Cell Res. 2015;25:985–988. doi: 10.1038/cr.2015.88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2015.88</ArticleId>
            <ArticleId IdType="pmc">PMC4528059</ArticleId>
            <ArticleId IdType="pubmed">26206313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park H.W., Kim Y.C., Yu B., Moroishi T., Mo J.S., Plouffe S.W., Meng Z., Lin K.C., Yu F.X., Alexander C.M., et al.  Alternative Wnt Signaling Activates YAP/TAZ. Cell. 2015;162:780–794. doi: 10.1016/j.cell.2015.07.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.07.013</ArticleId>
            <ArticleId IdType="pmc">PMC4538707</ArticleId>
            <ArticleId IdType="pubmed">26276632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao R., Salloum R., Xin M., Lu Q.R. The G protein Gαs acts as a tumor suppressor in sonic hedgehog signaling-driven tumorigenesis. Cell Cycle. 2016;15:1325–1330. doi: 10.1080/15384101.2016.1164371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384101.2016.1164371</ArticleId>
            <ArticleId IdType="pmc">PMC4889240</ArticleId>
            <ArticleId IdType="pubmed">27052725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao F., Xu Q., Zhao Y., Stevens J.V., Young S.H., Sinnett-Smith J., Rozengurt E. Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells. Mol. Cancer Res. 2017;15:929–941. doi: 10.1158/1541-7786.MCR-17-0023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-17-0023</ArticleId>
            <ArticleId IdType="pmc">PMC5645013</ArticleId>
            <ArticleId IdType="pubmed">28360038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng R., Gong J., Wu L., Wang L., Zhang B., Liang G., Zheng H., Xiao H. MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma. Oncol. Rep. 2017;38:1199–1205. doi: 10.3892/or.2017.5774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2017.5774</ArticleId>
            <ArticleId IdType="pubmed">28677804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorsam R.T., Gutkind J.S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer. 2007;7:79–94. doi: 10.1038/nrc2069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2069</ArticleId>
            <ArticleId IdType="pubmed">17251915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutkind J.S. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J. Biol. Chem. 1998;273:1839–1842. doi: 10.1074/jbc.273.4.1839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.273.4.1839</ArticleId>
            <ArticleId IdType="pubmed">9442012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieto Gutierrez A., McDonald P.H. GPCRs: Emerging anti-cancer drug targets. Cell. Signal. 2018;41:65–74. doi: 10.1016/j.cellsig.2017.09.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2017.09.005</ArticleId>
            <ArticleId IdType="pubmed">28931490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Raamsdonk C.D., Bezrookove V., Green G., Bauer J., Gaugler L., O’Brien J.M., Simpson E.M., Barsh G.S., Bastian B.C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599–602. doi: 10.1038/nature07586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07586</ArticleId>
            <ArticleId IdType="pmc">PMC2696133</ArticleId>
            <ArticleId IdType="pubmed">19078957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Raamsdonk C.D., Griewank K.G., Crosby M.B., Garrido M.C., Vemula S., Wiesner T., Obenauf A.C., Wackernagel W., Green G., Bouvier N., et al.  Mutations in GNA11 in Uveal Melanoma. N. Eng. J. Med. 2010;363:2191–2199. doi: 10.1056/NEJMoa1000584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1000584</ArticleId>
            <ArticleId IdType="pmc">PMC3107972</ArticleId>
            <ArticleId IdType="pubmed">21083380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F.X., Luo J., Mo J.S., Liu G., Kim Y.C., Meng Z., Zhao L., Peyman G., Ouyang H., Jiang W., et al.  Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014;25 doi: 10.1016/j.ccr.2014.04.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2014.04.017</ArticleId>
            <ArticleId IdType="pmc">PMC4075337</ArticleId>
            <ArticleId IdType="pubmed">24882516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., Wu Q., Depeille P., Chen P., Thornton S., Kalirai H., Coupland S.E., Roose J.P., Bastian B.C. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell. 2017;31:685–696. doi: 10.1016/j.ccell.2017.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC5499527</ArticleId>
            <ArticleId IdType="pubmed">28486107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huh J.Y., Kwon M.J., Seo K.Y., Kim M.K., Chae K.Y., Kim S.H., Ki C.S., Yoon M.S., Kim D.H. Novel nonsense GNAS mutation in a 14-month-old boy with plate-like osteoma cutis and medulloblastoma. J. Dermatol. 2014;41:319–321. doi: 10.1111/1346-8138.12284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1346-8138.12284</ArticleId>
            <ArticleId IdType="pubmed">24517547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y., Wu L.M.N., Bai S., Zhao C., Wang H., Wang J., Xu L., Sakabe M., Zhou W., Xin M., et al.  A reciprocal regulatory loop between TAZ/YAP and G-protein Gαs regulates Schwann cell proliferation and myelination. Nat. Commun. 2017;8:15161. doi: 10.1038/ncomms15161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15161</ArticleId>
            <ArticleId IdType="pmc">PMC5414202</ArticleId>
            <ArticleId IdType="pubmed">28443644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340:692–696. doi: 10.1038/340692a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/340692a0</ArticleId>
            <ArticleId IdType="pubmed">2549426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinstein L.S., Shenker A., Gejman P.V., Merino M.J., Friedman E., Spiegel A.M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Eng. J. Med. 1991;325:1688–1695. doi: 10.1056/NEJM199112123252403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199112123252403</ArticleId>
            <ArticleId IdType="pubmed">1944469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Hayre M., Degese M.S., Gutkind J.S. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr. Opin. Cell Biol. 2014;27:126–135. doi: 10.1016/j.ceb.2014.01.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2014.01.005</ArticleId>
            <ArticleId IdType="pmc">PMC4021379</ArticleId>
            <ArticleId IdType="pubmed">24508914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Hayre M., Vázquez-Prado J., Kufareva I., Stawiski E.W., Handel T.M., Seshagiri S., Gutkind J.S. The Emerging Mutational Landscape of G-proteins and G-protein Coupled Receptors in Cancer. Nat. Rev. Cancer. 2013;13:412–424. doi: 10.1038/nrc3521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3521</ArticleId>
            <ArticleId IdType="pmc">PMC4068741</ArticleId>
            <ArticleId IdType="pubmed">23640210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scales S.J., de Sauvage F.J. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol. Sci. 2009;30:303–312. doi: 10.1016/j.tips.2009.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2009.03.007</ArticleId>
            <ArticleId IdType="pubmed">19443052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araç D., Boucard A.A., Bolliger M.F., Nguyen J., Soltis S.M., Südhof T.C., Brunger A.T. A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. EMBO J. 2012;31:1364–1378. doi: 10.1038/emboj.2012.26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emboj.2012.26</ArticleId>
            <ArticleId IdType="pmc">PMC3321182</ArticleId>
            <ArticleId IdType="pubmed">22333914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández N.A., Correa E., Avila E.P., Vela T.A., Pérez V.M. PAR1 is selectively over expressed in high grade breast cancer patients: A cohort study. J. Transl. Med. 2009;7:47. doi: 10.1186/1479-5876-7-47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-7-47</ArticleId>
            <ArticleId IdType="pmc">PMC2704182</ArticleId>
            <ArticleId IdType="pubmed">19538737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bar-Shavit R., Maoz M., Kancharla A., Nag J.K., Agranovich D., Grisaru-Granovsky S., Uziely B. G Protein-Coupled Receptors in Cancer. Int. J. Mol. Sci. 2016;17 doi: 10.3390/ijms17081320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17081320</ArticleId>
            <ArticleId IdType="pmc">PMC5000717</ArticleId>
            <ArticleId IdType="pubmed">27529230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>St-Jean M., Ghorayeb N.E., Bourdeau I., Lacroix A. Aberrant G-protein coupled hormone receptor in adrenal diseases. Best Pract. Res. Clin. Endocrinol. Metab. 2018;32:165–187. doi: 10.1016/j.beem.2018.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.beem.2018.01.003</ArticleId>
            <ArticleId IdType="pubmed">29678284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G., Yu F.-X., Kim Y.C., Meng Z., Naipauer J., Looney D.J., Liu X., Gutkind J.S., Mesri E.A., Guan K.-L. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene. 2015;34:3536–3546. doi: 10.1038/onc.2014.281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2014.281</ArticleId>
            <ArticleId IdType="pmc">PMC4721508</ArticleId>
            <ArticleId IdType="pubmed">25195862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenhough A., Bagley C., Heesom K.J., Gurevich D.B., Gay D., Bond M., Collard T.J., Paraskeva C., Martin P., Sansom O.J., et al.  Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis. EMBO Mol. Med. 2018;10 doi: 10.15252/emmm.201708699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201708699</ArticleId>
            <ArticleId IdType="pmc">PMC6220329</ArticleId>
            <ArticleId IdType="pubmed">30143543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Pei H., Jia Y., Liu J., Li Z., Ai K., Lu Z., Lu L. Synergistic Tailoring of Electrostatic and Hydrophobic Interactions for Rapid and Specific Recognition of Lysophosphatidic Acid, an Early-Stage Ovarian Cancer Biomarker. J. Am. Chem. Soc. 2017;139:11616–11621. doi: 10.1021/jacs.7b06885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jacs.7b06885</ArticleId>
            <ArticleId IdType="pubmed">28782946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu D., Cai Y., Zhou W., Sheng J., Xu Z. The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis. Dis. Markers. 2018;2018:1984718. doi: 10.1155/2018/1984718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/1984718</ArticleId>
            <ArticleId IdType="pmc">PMC5875026</ArticleId>
            <ArticleId IdType="pubmed">29736193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramcharan S.K., Lip G.Y., Stonelake P.S., Blann A.D. Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes’ and AJCC stage in colorectal cancer. Eur. J. Clin. Invest. 2013;43:801–808. doi: 10.1111/eci.12108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/eci.12108</ArticleId>
            <ArticleId IdType="pubmed">23683169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hisai H., Kato J., Kobune M., Murakami T., Miyanishi K., Takahashi M., Yoshizaki N., Takimoto R., Terui T., Niitsu Y. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin. Cancer Res. 2003;9:4852–4859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14581357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 2006;16:405–411. doi: 10.1097/01.cmr.0000222598.27438.82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.cmr.0000222598.27438.82</ArticleId>
            <ArticleId IdType="pubmed">17013089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rykala J., Przybylowska K., Majsterek I., Pasz-Walczak G., Sygut A., Dziki A., Kruk-Jeromin J. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol. Oncol. Res. 2011;17:809–817. doi: 10.1007/s12253-011-9387-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12253-011-9387-6</ArticleId>
            <ArticleId IdType="pmc">PMC3185224</ArticleId>
            <ArticleId IdType="pubmed">21560015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton D.P., Cai A., Wendt K., Young M., Gamero A., De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin. Cancer Res. 1997;3:1579–1586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9815846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu-Chittenden Y., Huang B., Shim J.S., Chen Q., Lee S.-J., Anders R.A., Liu J.O., Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26:1300–1305. doi: 10.1101/gad.192856.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.192856.112</ArticleId>
            <ArticleId IdType="pmc">PMC3387657</ArticleId>
            <ArticleId IdType="pubmed">22677547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noland C.L., Gierke S., Schnier P.D., Murray J., Sandoval W.N., Sagolla M., Dey A., Hannoush R.N., Fairbrother W.J., Cunningham C.N. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling. Structure. 2016;24:179–186. doi: 10.1016/j.str.2015.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.str.2015.11.005</ArticleId>
            <ArticleId IdType="pubmed">26724994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan P., Han X., Zheng B., DeRan M., Yu J., Jarugumilli G.K., Deng H., Pan D., Luo X., Wu X. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat. Chem. Biol. 2016;12:282–289. doi: 10.1038/nchembio.2036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2036</ArticleId>
            <ArticleId IdType="pmc">PMC4798901</ArticleId>
            <ArticleId IdType="pubmed">26900866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Liu S., Ng E.Y., Li R., Poulsen A., Hill J., Pobbati A.V., Hung A.W., Hong W., Keller T.H., et al.  Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4. Biochem. J. 2018;475:2043–2055. doi: 10.1042/BCJ20180225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BCJ20180225</ArticleId>
            <ArticleId IdType="pubmed">29760238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bum-Erdene K., Zhou D., Gonzalez-Gutierrez G., Ghozayel M.K., Si Y., Xu D., Shannon H.E., Bailey B.J., Corson T.W., Pollok K.E., et al.  Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEADYap Protein-Protein Interaction. Cell Chem. Biol. 2019;26:378–389. doi: 10.1016/j.chembiol.2018.11.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2018.11.010</ArticleId>
            <ArticleId IdType="pubmed">30581134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao Y., Nakagawa K., Yang Z., Ikeda M., Withanage K., Ishigami-Yuasa M., Okuno Y., Hata S., Nishina H., Hata Y. A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J. Biochem. 2011;150:199–208. doi: 10.1093/jb/mvr063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jb/mvr063</ArticleId>
            <ArticleId IdType="pubmed">21586534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park H.W., Guan K.-L. Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol. Sci. 2013;34:581–589. doi: 10.1016/j.tips.2013.08.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2013.08.006</ArticleId>
            <ArticleId IdType="pmc">PMC3929107</ArticleId>
            <ArticleId IdType="pubmed">24051213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borcherding D.C., Tong W., Hugo E.R., Barnard D.F., Fox S., LaSance K., Shaughnessy E., Ben-Jonathan N. Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene. 2016;35:3103–3113. doi: 10.1038/onc.2015.369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.369</ArticleId>
            <ArticleId IdType="pmc">PMC5541367</ArticleId>
            <ArticleId IdType="pubmed">26477316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sever R., Brugge J.S. Signal transduction in cancer. Cold Spring Harb. Perspect. Med. 2015;5 doi: 10.1101/cshperspect.a006098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a006098</ArticleId>
            <ArticleId IdType="pmc">PMC4382731</ArticleId>
            <ArticleId IdType="pubmed">25833940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onken M.D., Makepeace C.M., Kaltenbronn K.M., Kanai S.M., Todd T.D., Wang S., Broekelmann T.J., Rao P.K., Cooper J.A., Blumer K.J. Targeting nucleotide exchange to inhibit constitutively active G protein α subunits in cancer cells. Sci. Signal. 2018;11:eaao6852. doi: 10.1126/scisignal.aao6852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.aao6852</ArticleId>
            <ArticleId IdType="pmc">PMC6279241</ArticleId>
            <ArticleId IdType="pubmed">30181242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Annala S., Feng X., Shridhar N., Eryilmaz F., Patt J., Yang J., Pfeil E.M., Cervantes-Villagrana R.D., Inoue A., Häberlein F., et al.  Direct targeting of Gαq and Gα11 oncoproteins in cancer cells. Sci. Signal. 2019;12:eaau5948. doi: 10.1126/scisignal.aau5948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.aau5948</ArticleId>
            <ArticleId IdType="pubmed">30890659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorrentino G., Ruggeri N., Specchia V., Cordenonsi M., Mano M., Dupont S., Manfrin A., Ingallina E., Sommaggio R., Piazza S., et al.  Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 2014;16:357–366. doi: 10.1038/ncb2936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2936</ArticleId>
            <ArticleId IdType="pubmed">24658687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oku Y., Nishiya N., Shito T., Yamamoto R., Yamamoto Y., Oyama C., Uehara Y. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio. 2015;5:542–549. doi: 10.1016/j.fob.2015.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fob.2015.06.007</ArticleId>
            <ArticleId IdType="pmc">PMC4506957</ArticleId>
            <ArticleId IdType="pubmed">26199863</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
